Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma-Reference-Cited by-同舟云学术

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma

Published:2023-08 Issue:8 Volume:4 Page:101133
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Pan Qiuzhong,Weng Desheng,Liu Jiayong,Han Zhaosheng,Ou Yusheng,Xu Bushu,Peng Ruiqing,Que Yi,Wen Xizhi,Yang Jing,Zhong Shi,Zeng Lun,Chen Aiyuan,Gong Haiping,Lin Yanmei,Chen Jiewen,Ma Ke,Lau Johnson Y.N.,Li Yi,Fan Zhengfu,Zhang Xing

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference41 articles.

1. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology;von Mehren;J. Natl. Compr. Cancer Netw.,2018

2. A nomogram to predict metastasis of soft tissue sarcoma of the extremities;Li;Medicine,2020

3. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

4. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up;Gronchi;Ann. Oncol.,2021

5. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease;Schöffski;Oncol. Res. Treat.,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development;Medical Sciences;2024-08-28

2. Frontiers and challenges of immune cell therapy research in solid tumors;Chinese Science Bulletin;2024-08-20

3. Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma;Cancer Research Communications;2024-07-01

4. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy;Experimental Hematology & Oncology;2024-04-03

5. The mast cell-T lymphocyte axis impacts cancer: Friend or foe?;Cancer Letters;2024-04